PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?

177Lu-DOTATATE peptide receptor radionuclide therapy: dose response in small intestinal neuroendocrine tumors

(2019) Ulrika Jahn et al.   NEUROENDOCRINOLOGY

Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

(2017) Anna Sundlöv et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

(2017) Jonathan Strosberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate

(2016) Hendrik Bergsma et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course

(2015) Hendrik Bergsma et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE

(2015) E. Ilan et al.   JOURNAL OF NUCLEAR MEDICINE

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY